VivoSim Announces Pricing of up to a $4 Million Public Offering VivoSim (Nasdaq: VIVS) priced a best-efforts public offering of up to $4.0 million, with an Initial Closing funding of $3.0 million expected on April 1, 2026 and a conditional Second Closing of $1.0 million on day 30 following the Initial Closing.The Initial Closing issues shares or pre-funded warrants at $1.140 per share (pre-funded warrant price $1.139), plus 3,947,369 common warrants exercisable at $1.710 for five years. The offering is led by a single family office with Joseph Gunnar & Co. as placement agent.

#VIVS VivoSim Announces Pricing of up to a $4 Million Public Offering

www.stocktitan.net/news/VIVS/vivo-sim-annou...

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation

#VIVS VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

www.stocktitan.net/news/VIVS/vivo-sim-relea...

Fundamental analysis of $VIVS (VivoSim Labs, INC.) based on financial data and reported results.

#VIVS

Most Searched, Thursday October 30, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Oct 30th - #LAC #FUBO #SOLS #EOSE #VIVS #JBLU #RXRX #LAES #BTBT #DVLT #DNN #CVU #ONDS #CMBM #WRD #USAR #RR #INTS #GRAB #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

News; ( NASDAQ: #VIVS ) Expected earnings - VivoSim Labs Inc.

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference VivoSim Labs (NASDAQ: VIVS) presented groundbreaking results for its NAMkind™ liver toxicology prediction platform at the Digestive Disease Week Conference. The platform demonstrated 87.5% sensitivity in predicting liver toxicity cases and 100% specificity in avoiding false positives. NAMkind™ uses physical organoid wet lab models from human donor cells and is developing AI-enhanced in silico predictions. This advancement aligns with FDA's recent initiative to phase out animal testing, targeting a >$10B market. VivoSim claims its technology could reduce drug development costs by 50% and significantly decrease late-stage clinical trial failures due to liver toxicity. The company's platform also addresses intestinal toxicity issues in cancer treatments, potentially improving chemotherapy dosing and reducing side effects.

#VIVS VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

www.stocktitan.net/news/VIVS/vivo-sim-prese...